Advertisement

Diabetologia

pp 1–10 | Cite as

Effect of Roux-en-Y gastric bypass surgery on diabetes remission and complications in individuals with type 2 diabetes: a Danish population-based matched cohort study

  • Lene R. MadsenEmail author
  • Lisbeth M. Baggesen
  • Bjørn Richelsen
  • Reimar W. Thomsen
Article

Abstract

Aims/hypothesis

The aim of this study was to examine the effect of Roux-en-Y gastric bypass (RYGB) surgery on diabetes remission, subsequent diabetes relapse and micro- and macrovascular complications in individuals with type 2 diabetes and obesity (BMI >35 kg/m2) in a real-world setting.

Methods

This was a population-based cohort study of 1111 individuals with type 2 diabetes treated by RYGB at hospitals in Northern Denmark (2006–2015), and 1074 matched non-operated individuals with type 2 diabetes. Diabetes remission was defined as no glucose-lowering drug use with HbA1c <48 mmol/mol (<6.5%), or metformin monotherapy with HbA1c <42 mmol/mol (<6.0%). Data on complications were ascertained from medical registries with complete follow-up.

Results

At 1 year of follow-up, 74% of the cohort treated by RYGB experienced diabetes remission, while 27% had relapsed after 5 years. Predictors of non-remission were age >50 years, diabetes duration >5 years, use of glucose-lowering drugs other than metformin, and baseline HbA1c >53 mmol/mol (>7.0%). Compared with the non-operated cohort using adjusted Cox regression (5.3 years follow-up), the cohort treated by RYGB had 47% lower risk of microvascular complications (HR 0.53 [95% CI 0.38, 0.73]) and a statistically non-significant 24% lower risk of macrovascular complications (HR 0.76 [95% CI 0.49, 1.18]). Diabetes remission vs non-remission at 1 year was associated with reduced HR of 0.43 (95% CI 0.25, 0.72) for microvascular complications and with HR of 0.76 (95% CI 0.40, 1.45) for macrovascular complications.

Conclusions/interpretation

In routine clinical care, three out of four individuals with type 2 diabetes and obesity treated by RYGB experienced diabetes remission after 1 year, whereas 27% of these individuals had relapsed at 5 years follow-up. RYGB was associated with substantially decreased risk of microvascular complications and non-significantly fewer macrovascular complications, with early diabetes remission as a clear predictor of reduced microvascular complications.

Keywords

Diabetes remission Gastric bypass Macrovascular complications Microvascular complications Population-based study Roux-en-Y gastric bypass Type 2 diabetes 

Abbreviations

CCI

Charlson comorbidity index

CRS

Danish Civil Registration System

DNHPD

Danish National Health Service Prescription Database

DNPR

Danish National Patients Registry

GLD

Glucose-lowering drug

IQR

Interquartile range

IR

Incidence rate

IRR

Incidence rate ratio

RYGB

Roux-en-Y gastric bypass

SOS

Swedish Obese Subjects

Notes

Acknowledgements

The Department of Clinical Epidemiology is a member of the Danish Centre for Strategic Research in Type 2 Diabetes (DD2), supported by the Danish Agency for Science (09-067009, 09-075724), the Danish Health and Medicines Authority, the Danish Diabetes Association and an unrestricted donation from Novo Nordisk A/S. Project partners are listed at https://dd2.nu/. The Department of Clinical Epidemiology participates in the International Diabetic Neuropathy Consortium (IDNC) research programme, which is supported by a Novo Nordisk Foundation Challenge programme grant (NNF14SA000 6).

Contribution statement

LRM designed the study, researched the data and drafted the manuscript. LMB designed the study and performed the statistical analysis. BR and RWT designed the study and revised the manuscript critically. All authors contributed to the discussion and approved the final manuscript. LRM is the guarantor for the content of this article.

Funding

LRM is affiliated to the Danish Diabetes Academy funded by the Novo Nordisk Foundation. The study was funded by the Health Research Fund of Central Denmark, the Novo Nordisk Foundation and the A. P. Møller Foundation. The study sponsors were not involved in the design of the study, the collection, analysis and interpretation of data, writing the report or the decision to submit the report for publication.

Duality of interest

The authors declare that there is no duality of interest associated with this manuscript.

Supplementary material

125_2019_4816_MOESM1_ESM.pdf (401 kb)
ESM (PDF 401 kb)

References

  1. 1.
    Davies MJ, DʼAlessio DA, Fradkin J et al (2018) Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41(12):2669–2701.  https://doi.org/10.2337/dci18-0033 CrossRefGoogle Scholar
  2. 2.
    Cummings DE, Rubino F (2018) Metabolic surgery for the treatment of type 2 diabetes in obese individuals. Diabetologia 61(2):257–264.  https://doi.org/10.1007/s00125-017-4513-y CrossRefGoogle Scholar
  3. 3.
    Angrisani L, Santonicola A, Iovino P et al (2017) Bariatric surgery and endoluminal procedures: IFSO worldwide survey 2014. Obes Surg 27(9):2279–2289.  https://doi.org/10.1007/s11695-017-2666-x CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Courcoulas AP, Belle SH, Neiberg RH et al (2015) Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment: a randomized clinical trial. JAMA Surg 150(10):931–940.  https://doi.org/10.1001/jamasurg.2015.1534 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Courcoulas AP, King WC, Belle SH et al (2018) Seven-year weight trajectories and health outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) study. JAMA Surg 153(5):427–434.  https://doi.org/10.1001/jamasurg.2017.5025 CrossRefGoogle Scholar
  6. 6.
    Ikramuddin S, Billington CJ, Lee WJ et al (2015) Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. Lancet Diabetes Endocrinol 3(6):413–422.  https://doi.org/10.1016/S2213-8587(15)00089-3 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Cummings DE, Arterburn DE, Westbrook EO et al (2016) Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. Diabetologia 59(5):945–953.  https://doi.org/10.1007/s00125-016-3903-x CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Halperin F, Ding SA, Simonson DC et al (2014) Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg 149(7):716–726.  https://doi.org/10.1001/jamasurg.2014.514 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Arterburn DE, Bogart A, Sherwood NE et al (2013) A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 23(1):93–102.  https://doi.org/10.1007/s11695-012-0802-1 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Yip S, Plank LD, Murphy R (2013) Gastric bypass and sleeve gastrectomy for type 2 diabetes: a systematic review and meta-analysis of outcomes. Obes Surg 23(12):1994–2003.  https://doi.org/10.1007/s11695-013-1030-z CrossRefGoogle Scholar
  11. 11.
    Still CD, Wood GC, Benotti P et al (2014) Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. Lancet Diabetes Endocrinol 2(1):38–45.  https://doi.org/10.1016/S2213-8587(13)70070-6 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Schauer PR, Bhatt DL, Kirwan JP et al (2017) Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med 376(7):641–651.  https://doi.org/10.1056/NEJMoa1600869 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Mingrone G, Panunzi S, De Gaetano A et al (2015) Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 386(9997):964–973.  https://doi.org/10.1016/S0140-6736(15)00075-6 CrossRefGoogle Scholar
  14. 14.
    Wolfe BM, Belle SH (2014) Long-term risks and benefits of bariatric surgery: a research challenge. JAMA 312(17):1792–1793.  https://doi.org/10.1001/jama.2014.12966 CrossRefGoogle Scholar
  15. 15.
    Isaman DJM, Rothberg AE, Herman WH (2018) The effect of attrition on reported diabetes remission rates following Roux-en-Y gastric bypass: a sensitivity analysis. Obes Surg 28(5):1308–1312.  https://doi.org/10.1007/s11695-017-2995-9 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Sjostrom L, Peltonen M, Jacobson P et al (2014) Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 311(22):2297–2304.  https://doi.org/10.1001/jama.2014.5988 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Johnson BL, Blackhurst DW, Latham BB et al (2013) Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. J Am Coll Surg 216(4):545–556; discussion 556-558.  https://doi.org/10.1016/j.jamcollsurg.2012.12.019 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    O’Brien R, Johnson E, Haneuse S et al (2018) Microvascular outcomes in patients with diabetes after bariatric surgery versus usual care: a matched cohort study. Ann Intern Med 169(5):300–310.  https://doi.org/10.7326/M17-2383 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Schmidt M, Pedersen L, Sorensen HT (2014) The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29(8):541–549.  https://doi.org/10.1007/s10654-014-9930-3 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lynge E, Sandegaard JL, Rebolj M (2011) The Danish National Patient Register. Scand J Public Health 39(7_suppl):30–33.  https://doi.org/10.1177/1403494811401482 CrossRefGoogle Scholar
  21. 21.
    Johannesdottir SA, Horvath-Puho E, Ehrenstein V, Schmidt M, Pedersen L, Sorensen HT (2012) Existing data sources for clinical epidemiology: the Danish National Database of Reimbursed Prescriptions. Clin Epidemiol 4:303–313.  https://doi.org/10.2147/CLEP.S37587 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Grann AF, Erichsen R, Nielsen AG, Froslev T, Thomsen RW (2011) Existing data sources for clinical epidemiology: the clinical laboratory information system (LABKA) research database at Aarhus University, Denmark. Clin Epidemiol 3:133–138.  https://doi.org/10.2147/CLEP.S17901 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Sundhedsstyrelsen D (2008) Forløbsprogram for diabetes. Available from: https://www.sst.dk/~/media/5C35B9DEA91B4E0A91458076F1994019.ashx, accessed 7 Jun 2017
  24. 24.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383.  https://doi.org/10.1016/0021-9681(87)90171-8 CrossRefGoogle Scholar
  25. 25.
    Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT (2011) The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 11(1):83.  https://doi.org/10.1186/1471-2288-11-83 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Thomsen RW, Baggesen LM, Svensson E et al (2015) Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment: a 13-year population-based cohort study. Diabetes Obes Metab 17(8):771–780.  https://doi.org/10.1111/dom.12484 CrossRefGoogle Scholar
  27. 27.
    Buse JB, Caprio S, Cefalu WT et al (2009) How do we define cure of diabetes? Diabetes Care 32(11):2133–2135.  https://doi.org/10.2337/dc09-9036 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M (2003) The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 56(2):124–130.  https://doi.org/10.1016/S0895-4356(02)00591-7 CrossRefGoogle Scholar
  29. 29.
    Wildenschild C, Mehnert F, Thomsen RW et al (2013) Registration of acute stroke: validity in the Danish Stroke Registry and the Danish National Registry of Patients. Clin Epidemiol 6:27–36CrossRefGoogle Scholar
  30. 30.
    Gribsholt SB, Svensson E, Richelsen B, Raundahl U, Sorensen HT, Thomsen RW (2018) Rate of acute hospital admissions before and after Roux-en-Y gastric bypass surgery: a population-based cohort study. Ann Surg 267(2):319–325.  https://doi.org/10.1097/SLA.0000000000002113 CrossRefGoogle Scholar
  31. 31.
    Dicker D, Yahalom R, Comaneshter DS, Vinker S (2016) Long-term outcomes of three types of bariatric surgery on obesity and type 2 diabetes control and remission. Obes Surg 26(8):1814–1820.  https://doi.org/10.1007/s11695-015-2025-8 CrossRefGoogle Scholar
  32. 32.
    UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865Google Scholar
  33. 33.
    Debedat J, Sokolovska N, Coupaye M et al (2018) Long-term relapse of type 2 diabetes after Roux-en-Y gastric bypass: prediction and clinical relevance. Diabetes Care 41(10):2086–2095.  https://doi.org/10.2337/dc18-0567 CrossRefGoogle Scholar
  34. 34.
    Adams TD, Davidson LE, Litwin SE et al (2017) Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med 377(12):1143–1155.  https://doi.org/10.1056/NEJMoa1700459 CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Coleman KJ, Haneuse S, Johnson E et al (2016) Long-term microvascular disease outcomes in patients with type 2 diabetes after bariatric surgery: evidence for the legacy effect of surgery. Diabetes Care 39(8):1400–1407.  https://doi.org/10.2337/dc16-0194 CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Harper J, Madan AK, Ternovits CA, Tichansky DS (2007) What happens to patients who do not follow-up after bariatric surgery? Am Surg 73:181–184Google Scholar
  37. 37.
    Grundy SM, Benjamin IJ, Burke GL et al (1999) Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100(10):1134–1146.  https://doi.org/10.1161/01.CIR.100.10.1134 CrossRefGoogle Scholar
  38. 38.
    Christensen DH, Nicolaisen SK, Berencsi K et al (2018) Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort of newly diagnosed patients with type 2 diabetes: a cohort profile. BMJ Open 8(4):e017273.  https://doi.org/10.1136/bmjopen-2017-017273 CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Gribsholt SB, Pedersen L, Richelsen B, Dekkers O, Thomsen RW (2018) Body mass index of 92,027 patients acutely admitted to general hospitals in Denmark: associated clinical characteristics and 30-day mortality. PLoS One 13(4):e0195853.  https://doi.org/10.1371/journal.pone.0195853 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Yska JP, van Roon EN, de Boer A, et al (2015) Remission of type 2 diabetes mellitus in patients after different types of bariatric surgery: a population-based cohort study in the United Kingdom. JAMA Surg 150(12):1126–1133Google Scholar
  41. 41.
    Upala S, Jaruvongvanich V, Sanguankeo A (2016) Risk of nephrolithiasis, hyperoxaluria, and calcium oxalate supersaturation increased after Roux-en-Y gastric bypass surgery: a systematic review and meta-analysis. Surg Obes Relat Dis 12(8):1513–1521.  https://doi.org/10.1016/j.soard.2016.04.004 CrossRefGoogle Scholar
  42. 42.
    Carlsson LM, Peltonen M, Ahlin S et al (2012) Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 367(8):695–704.  https://doi.org/10.1056/NEJMoa1112082 CrossRefGoogle Scholar
  43. 43.
    Shulman A, Peltonen M, Sjostrom CD et al (2018) Incidence of end-stage renal disease following bariatric surgery in the Swedish Obese Subjects Study. Int J Obes 42(5):964–973.  https://doi.org/10.1038/s41366-018-0045-x CrossRefGoogle Scholar
  44. 44.
    Eliasson B, Liakopoulos V, Franzen S et al (2015) Cardiovascular disease and mortality in patients with type 2 diabetes after bariatric surgery in Sweden: a nationwide, matched, observational cohort study. Lancet Diabetes Endocrinol 3(11):847–854.  https://doi.org/10.1016/S2213-8587(15)00334-4 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Lene R. Madsen
    • 1
    Email author
  • Lisbeth M. Baggesen
    • 2
  • Bjørn Richelsen
    • 1
  • Reimar W. Thomsen
    • 2
  1. 1.Department of Endocrinology and Internal MedicineAarhus University HospitalAarhus NDenmark
  2. 2.Department of Clinical EpidemiologyAarhus University HospitalAarhusDenmark

Personalised recommendations